Rinafloem Sustained Release Tablet 25/5/1000 mg (Empagliflozin, Linagliptin, Metformin Hydrochloride)
Empagliflozin 25mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
MFDS item code 202502782 · Approved 2025.10.28
Improvement of glycemic control in patients with type 2 diabetes mellitus
This drug helps improve blood sugar control in patients with type 2 diabetes. The three ingredients—empagliflozin, linagliptin, and metformin—work together to enhance the effectiveness of diet and exercise therapy. This allows for more effective management of blood sugar levels. When used alongside consistent use and lifestyle improvements, it greatly aids in blood sugar control. This drug is used to enhance blood sugar control in patients with type 2 diabetes.
For antidiabetic therapy, the dose of this medicine is determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily doses of each component: empagliflozin 25mg, linagliptin 5mg, and extended-release metformin hydrochloride 2000mg. This medicine should be taken once daily in the evening with a meal to reduce gastrointestinal adverse reactions caused by metformin hydrochloride. If the dose of metformin hydrochloride needs to be adjusted, adjust it gradually. Patients taking this medicine as 10/5/1000mg or 25/5/1000mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 5/2.5/1000mg or 12.5/2.5/1000mg extended-release tablets should take 2 tablets per dose once daily. If additional glycemic control is needed in patients who tolerate the recommended starting dose of this medicine, empagliflozin 10mg/linagliptin 5mg/metformin hydrochloride 1000mg once daily, the dose of empagliflozin or metformin may be increased. Patients switching to this medicine from concomitant empagliflozin, linagliptin, and metformin hydrochloride therapy should receive the same doses they were taking previously. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of its metformin hydrochloride component if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If the eGFR decreases to below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
This drug can rarely cause serious lactic acidosis, so if symptoms such as fatigue, muscle pain, breathing difficulty, or abdominal pain appear, immediate medical attention should be sought. This drug should not be used in patients with allergies to the main or constituent components, patients with type 1 diabetes, patients with severely impaired kidney function, patients on dialysis, or patients with acute or chronic metabolic acidosis. Kidney function should be regularly checked to ensure it is normal, and if kidney function deteriorates, the use of this drug should be discontinued. In situations such as acute infections, dehydration, heart failure, myocardial infarction, or before and after surgery, the administration of this drug should be temporarily halted, and it can be resumed once the condition is stable. This drug can cause hypoglycemia, so blood sugar levels should be carefully monitored, especially when taken with insulin or sulfonylurea medications, and the dosage of the hypoglycemic agent may need adjustment if necessary. During the use of this drug, urinary tract infections or genital infections may occur, so treatment should be sought immediately if symptoms of infection appear. Patients at risk of fluid loss or dehydration, the elderly, and patients with cardiovascular diseases should periodically check blood pressure and fluid status when taking this drug. This drug is not recommended for patients with impaired liver function or those who consume excessive alcohol. This drug should be taken as a tablet and swallowed whole without crushing or chewing, and it is normal for the tablet coating to be excreted in feces. Patients who are pregnant or have problems with placental function, and pregnant women at risk of pre-eclampsia should not take this drug. Caution should be exercised during driving or operating machinery due to the risk of accidents caused by hypoglycemia while taking this drug. This drug may interact with other medications, so patients should be sure to inform healthcare providers about any other medications they are taking.
Not everyone experiences these, and they can vary from person to person.
This drug must be stored in a tightly sealed container to prevent exposure to air or moisture, and the storage temperature must be maintained at room temperature between 1 and 30 degrees Celsius. Storing it this way can help preserve the drug's effectiveness for a long time.
Oval-shaped sustained-release film-coated tablets that are white and light orange, both sides convex
Bottle packaging - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 10mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 12.5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.